Literature DB >> 28245053

Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer.

J S Chang1, K H Kim1, H I Yoon1, W J Hyung2, S Y Rha3, H S Kim3, Y C Lee4, J S Lim5, S H Noh2, W S Koom1.   

Abstract

BACKGROUND: Risk for and site of locoregional relapse have not been well studied in patients undergoing gastrectomy with D2 lymphadenectomy for gastric cancer.
METHODS: Patients who had undergone gastrectomy with D2 lymphadenectomy for gastric cancer between 2004 and 2007 were identified from an institutional database. The locoregional relapse rate was estimated by competing risk analysis, and risk groups were derived according to locoregional relapse risk using recursive partitioning analysis (RPA). The locations of nodal relapses were evaluated according to Japanese Classification of Gastric Carcinoma criteria.
RESULTS: Some 2618 patients were included. With a median follow-up of 78·0 (range 28·5-122·6) months, relapse was diagnosed in 471 of 2618 patients (18·0 per cent). The cumulative incidence of locoregional relapse at 5 years was 8·5 (95 per cent c.i. 7·4 to 9·6) per cent. The 5-year locoregional recurrence rates for high-risk (N3), intermediate-risk (N1-2) and low-risk (N0) groups were 32·4, 12·3 and 1·7 per cent respectively (P < 0·001). Among patients with regional relapse, 90·4 per cent had involvement outside the D2 dissected area, and the most commonly involved site was station 16b1. This pattern was maintained in the RPA risk groups (P = 0·329).
CONCLUSION: Locoregional relapse at 5 years after gastrectomy with D2 lymphadenectomy was 8·5 per cent, and was most often seen outside the D2 dissected area.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28245053     DOI: 10.1002/bjs.10502

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

Review 1.  Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives.

Authors:  Valentina Mengardo; Maria Bencivenga; Jacopo Weindelmayer; Michele Pavarana; Simone Giacopuzzi; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2018-05-30

2.  A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial.

Authors:  Naoto Takahashi; Mitsuro Kanda; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Katsufumi Miyamoto; Yuichi Ito; Osamu Takayama; Motohiro Imano; Norio Mitsumori; Junichi Sakamoto; Satoshi Morita; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2018-03-13       Impact factor: 7.370

3.  Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country.

Authors:  Eugenia Cordero-García; Allan Ramos-Esquivel; Warner Alpízar-Alpízar
Journal:  J Gastrointest Oncol       Date:  2018-02

4.  The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data.

Authors:  Bin-Bin Xu; Jun Lu; Zhi-Fang Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Gastric Cancer       Date:  2019-02-09       Impact factor: 7.701

5.  Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis.

Authors:  Yiquan Jiang; Yanhong Su; Yutong Chen; Zhiyong Li
Journal:  J Cancer       Date:  2017-08-23       Impact factor: 4.207

6.  D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature.

Authors:  Laura Lorenzon; Rosina Giudicissi; Marco Scatizzi; Genoveffa Balducci; Stefano Cantafio; Alberto Biondi; Roberto Persiani; Paolo Mercantini; Domenico D'Ugo
Journal:  BMC Surg       Date:  2020-06-10       Impact factor: 2.102

Review 7.  Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition.

Authors:  Jing Xu; Jonathan Zhu; Qichun Wei
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

Review 8.  Precision Medicine in Non Communicable Diseases.

Authors:  Mandana Hasanzad; Negar Sarhangi; Hamid Reza Aghaei Meybodi; Shekoufeh Nikfar; Fatemeh Khatami; Bagher Larijani
Journal:  Int J Mol Cell Med       Date:  2019-07-25

9.  Does three-dimensional surgery affect recurrence patterns in patients with gastric cancer after laparoscopic R0 gastrectomy? Results from a 3-year follow-up phase III trial.

Authors:  Jun Lu; Bin-Bin Xu; Zhi-Fang Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Surg Endosc       Date:  2020-01-17       Impact factor: 4.584

10.  Is There Any Role for Super-Extended Limphadenectomy in Advanced Gastric Cancer? Results of an Observational Study from a Western High Volume Center.

Authors:  Maria Bencivenga; Giuseppe Verlato; Valentina Mengardo; Lorenzo Scorsone; Michele Sacco; Lorena Torroni; Simone Giacopuzzi; Giovanni de Manzoni
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.